ACTRN12616000775415
Completed
未知
A randomised, controlled, single blinded cross-over trial to investigate the effect of Zespri SunGold kiwifruit on digestive health and gut health function in individuals with constipation with or without Irritable Bowel Syndrome.
The New Zealand Institute for Plant & Food Research0 sites50 target enrollmentJune 14, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Constipation
- Sponsor
- The New Zealand Institute for Plant & Food Research
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Functionally Constipated Group and Irritable Bowel Sydrome with constipation group: Adult (18\-65 years), BMI 18\-25, Both male and female (females will be required to declare stage of menstrual cycle during different trial stages), Presence of Functional Constipation or Irritable Bowel Syndrome according to ROME III diagnostic criteria.
Exclusion Criteria
- •1\. Alarm features associated with bowel habit (recent changes in bowel habit (\<3 months), rectal bleeding, weight loss, blood in stools, bleeding haemorrhoids, family history of Gastrointestinal (GI) cancer or Irritable Bowel Disease (IBD).
- •2\. Chronic disease (cardiovascular, cancer, renal failure, previous GI surgery (not including appendectomy or cholecystectomy), neurological conditions (e.g. stroke, spinal chord injury, multiple sclerosis)
- •3\. Fasting blood glucose of 6\.0 mmol/l or greater. Participants will be screened during recruitment.
- •4\. Participants with diagnosed and stable conditions requiring the use of selective serotonin uptake inhibitors, triglycerides, opiates or anti\-inflammatories will only be permitted into the trial on condition that the medication has been in use continually and the condition has been stable for \> 3 months. Similarly those with stable and controlled diabetes for \> 3 months will also be permitted to take part in the study.
- •5\. Women who are pregnant, breastfeeding or planning a pregnancy in the 3 months post selection will be excluded.
- •6\. Potential participants with known kiwifruit or latex allergy will be excluded.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy compared between bilastine, desloratadine, rupatadine and placebo in reduction of histamine-induced skin reactivity in healthy volunteers.ALLERGIC RHINOCONJUNTIVITIS AND CHRONIC URTICARIATherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2015-000790-13-ESFAES FARMA, S.A.
Active, not recruiting
Phase 1
A randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy.The intended indication is:Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.MedDRA version: 17.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]EUCTR2013-004888-31-ITMundipharma Research GmbH & Co. KG217
Active, not recruiting
Phase 1
A study which will show the equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-cancer or cancer pain that requires around-the-clock opioid therapy.EUCTR2013-004888-31-GBMundipharma Research GmbH & Co. KG220
Active, not recruiting
Phase 1
A study which will show the equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-cancer or cancer pain that requires around-the-clock opioid therapy.The intended indication is:Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.MedDRA version: 17.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]EUCTR2013-004888-31-ESMundipharma Research GmbH & Co. KG200
Active, not recruiting
Phase 1
A study which will show the equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-cancer or cancer pain that requires around-the-clock opioid therapy.EUCTR2013-004888-31-CZMundipharma Research GmbH & Co. KG217